OTTAVA FDA Nod Adds Long-Term MedTech Option, Doesn't Alter Near-Term Challenges

What happened

Johnson & Johnson received U.S. FDA De Novo authorization for its OTTAVA robotic surgical system, marking a long-awaited entry into the competitive surgical robotics market with a table-integrated platform. The company is framing OTTAVA as a long-term growth initiative within its MedTech segment, but commercialization and meaningful revenue contribution are likely years away. This development arrives against a backdrop of significant near-term headwinds, including accelerating STELARA biosimilar erosion driven by upcoming CVS formulary changes and persistent talc litigation overhang. With over 75,000 talc plaintiffs pending and management unable to estimate potential losses, the legal risk remains unbounded. While OTTAVA adds a future growth layer, it does not offset the immediate need for STELARA stabilization and talc clarity before the investment case improves.

Implication

The FDA authorization validates JNJ’s entry into robotic surgery, but the platform must now demonstrate clinical adoption and compete against the entrenched da Vinci system. Commercialization will require significant investment and a multi-year ramp, limiting its ability to offset STELARA erosion over the next 12-18 months. The stock’s near-term direction will be driven by how STELARA volumes hold post-July 1, 2026 CVS formulary shift and any talc evidentiary rulings. If immunology growth disappoints or talc reserves need to increase, the shares remain exposed to the bear case down to $190. Thus, while OTTAVA is a positive signal, it does not provide a reason to upgrade until after Q2-Q3 FY2026 results confirm stabilization.

Thesis delta

The OTTAVA authorization introduces a new long-term MedTech growth driver but does not alter the WAIT rating. The thesis remains anchored on monitoring STELARA erosion following the CVS formulary change and bounding talc exposure, with better entry points likely after Q2-Q3 FY2026 data.